Work

Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance

Year: 2018

Type: article

Abstract: Objectives: The aim of this study is to investigate the predictive value of smoking history on treatment outcomes of pemetrexed continuation maintenance therapy in advanced non-squamous NSCLC patients without EGFR mutations and ALK rearrangements.Methods: 71 consecutive EGFR and ALK negative advanced non-squamous NSCLC patients who had received pemetrexed continuation maintenance therapy at least two cycles were retrospectively analyzed in our single center.The enrolled patients were categorized into two groups as never-/former light smokers and current smokers according to their smoking history.Results: In the 71 non-squamous NSCLC patients, 30 (42.3%) were never-/former light smokers and 41 (57.7%) were current smokers.The objective response rate (ORR) of never-/former light smokers was significantly higher than that of current smokers (26.7% vs. 7.3%, p = 0.026).Never-/former light smokers showed significantly longer progression free survival (PFS) (6.6 [95% CI 5.3-7.9]months vs. 5.1 [95% CI 3.5-6.7]months; HR: 0.557, 95% CI 0.339-0.915,p = 0.021) and overall survival (OS) (17.3 [95% CI 14.4-20.2]months vs. 15.7 [95% CI 12.0-19.4]months; HR: 0.578, 95% CI 0.338-0.986,p = 0.044) than current smokers.Multivariate analysis identified smoking history was an independent predictive factor for PFS and OS.Conclusions: Current smoking is an independent negative predictive factor of outcomes for pemetrexed continuation maintenance therapy in advanced non-squamous NSCLC patients without EGFR mutations and ALK rearrangements.

Source: Journal of Cancer

DOI: 10.7150/jca.24872